Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Effect of Y-3 on Rosuvastatin in Healthy Participants
NCT07692685Phase 1Completed
- Sponsor
- NeuroDawn
- Start
- May 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of loberamisal, sponsored by NeuroDawn. Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration of Rosuvastatin and Area Under the Curve from Time Zero to Infinity of Rosuvastatin. Started May 2026; status: completed.
02
Drugs
loberamisal
Beyond the preview
Go deeper on NCT07692685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07692685.